CSL CEO Participates in White House Roundtable Urging COVID-19 Plasma Donations

Read About the Meeting

CSL Behring Begins Trial to Evaluate Monoclonal Antibody

Our Commitment to Fighting COVID-19

CSL Behring Engaged The Economist Intelligence Unit to Write a White Paper on Rare Disease in Asia-Pacific

Read The Findings

Popular search terms:

Paul Perreault

COVID-19: A Message from Our CEO

"As the COVID-19 pandemic evolves, CSL remains committed to safeguarding our patients, our donors and our people. In keeping with our values-based culture, CSL has taken precautions to ensure our employees and our facilities remain safe so we can continue to deliver on our promise to patients and public health." - Paul Perreault, CEO & Managing Director, CSL Limited

CSL CEO Paul Perreault at White House Roundtable

At White House Roundtable, Paul Perreault Urges People to Donate Plasma in the Fight Against COVID-19

30 Jul 2020
Suffering in Silence Icon

Rare Diseases in Asia-Pacific

Economist Intelligence Unit (EIU) Report launched today reveals only one in three rare disease patients receives the best-ava…

16 Jul 2020
coronavirus

CSL’s Global Role in Battling COVID-19

Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19 …

14 Jul 2020

Get to Know Us Better

Scientists in Marburg, Germany
Analytical Services Quality Employee Angelika Jung

Angelika Jung

Senior Manager, ASQ Group Leader External Materials & Sampling (Marburg, Germany)

Angelika has been with CSL Behring for nearly 20 years and in that time has grown from having no direct reports to leading a large team in our Quality group.

Watch Angelika's Story